Use of inotuzumab-ozogamicin in a child with Down syndrome and refractory B-cell precursor acute lymphoblastic leukemia

被引：4
|
作者：
Murillo, Laura [1 ]
Luis Dapena, Jose [1 ]
Velasco, Pablo [1 ]
Diaz de Heredia, Cristina [1 ]
机构：
[1] Hosp Univ Vall dHebron, Serv Oncol & Hematol Pediat, Passeig Vall dHebron 119-129, Barcelona 08035, Spain
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷 / 04期
关键词：
MINIMAL RESIDUAL DISEASE; PROGNOSTIC-FACTORS; PEDIATRIC-PATIENTS; TRANSPLANTATION;
D O I：
10.1002/pbc.27562
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia
    Thota, Swapna
    Advani, Anjali
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 98 (05) : 425 - 434
  • [2] Inotuzumab Ozogamicin Monotherapy as an Outpatient Salvage Treatment in Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia: Compassionate Access
    Radhakrishnan, Vivek S.
    Modak, Ketan
    Bhave, Saurabh J.
    Kumar, Jeevan
    Roychowdhury, Mita
    Ghosh, Manik
    Parihar, Mayur
    Arora, Neeraj
    Mishra, Deepak K.
    Nair, Reena
    Chandy, Mammen
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2021, 42 (02) : 199 - 203
  • [3] Inotuzumab ozogamicin for relapse prevention in a boy with Down syndrome and relapsed acute lymphoblastic leukemia
    Kohso, Atsushi
    Toyoda, Hidemi
    Hanaki, Ryo
    Niwa, Kaori
    Okumura, Yosuke
    Morimoto, Mari
    Ito, Takahiro
    Hirayama, Masahiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025, 121 (02) : 276 - 280
  • [4] Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
    DeAngelo, Daniel J.
    Advani, Anjali S.
    Marks, David, I
    Stelljes, Matthias
    Liedtke, Michaela
    Stock, Wendy
    Goekbuget, Nicola
    Jabbour, Elias
    Merchant, Akil
    Wang, Tao
    Vandendries, Erik
    Neuhof, Alexander
    Kantarjian, Hagop
    O'Brien, Susan
    BLOOD CANCER JOURNAL, 2020, 10 (08)
  • [5] Blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
    Queudeville, Manon
    Schlegel, Patrick
    Heinz, Amadeus T.
    Lenz, Teresa
    Doering, Michaela
    Holzer, Ursula
    Hartmann, Ulrike
    Kreyenberg, Hermann
    von Stackelberg, Arend
    Schrappe, Martin
    Zugmaier, Gerhard
    Feuchtinger, Tobias
    Lang, Peter
    Handgretinger, Rupert
    Ebinger, Martin
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 106 (04) : 473 - 483
  • [6] Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia
    Marks, David, I
    Kebriaei, Partow
    Stelljes, Matthias
    Goekbuget, Nicola
    Kantarjian, Hagop
    Advani, Anjali S.
    Merchant, Akil
    Stock, Wendy
    Cassaday, Ryan D.
    Wang, Tao
    Zhang, Hui
    Loberiza, Fausto
    Vandendries, Erik
    DeAngelo, Daniel J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (09) : 1720 - 1729
  • [7] Initial Experience With CMC-544 (Inotuzumab Ozogamicin) in Pediatric Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
    Rytting, Michael
    Triche, Lisa
    Thomas, Deborah
    O'Brien, Susan
    Kantarjian, Hagop
    PEDIATRIC BLOOD & CANCER, 2014, 61 (02) : 369 - 372
  • [8] Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia
    Badar, Talha
    Szabo, Aniko
    Dinner, Shira
    Liedtke, Michaela
    Burkart, Madelyn
    Shallis, Rory M.
    Yurkiewicz, Ilana R.
    Kuo, Eric
    Khan, Muhammad Ali
    Balasubramanian, Suresh
    Yang, Jay
    Hefazi, Mehrdad
    Podoltsev, Nikolai
    Patel, Anand
    Curran, Emily
    Wang, Amy
    Arslan, Shukaib
    Aldoss, Ibrahim
    Siebenaller, Caitlin
    Mattison, Ryan J.
    Litzow, Mark R.
    Wadleigh, Martha
    Advani, Anjali S.
    Atallah, Ehab
    CANCER, 2021, 127 (07) : 1039 - 1048
  • [9] Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia - role of blinatumomab
    Queudeville, Manon
    Handgretinger, Rupert
    Ebinger, Martin
    ONCOTARGETS AND THERAPY, 2017, 10 : 3567 - 3578
  • [10] Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia
    Goekbuget, Nicola
    Kantarjian, Hagop M.
    Brueggemann, Monika
    Stein, Anthony S.
    Bargou, Ralf C.
    Dombret, Herve
    Fielding, Adele K.
    Heffner, Leonard
    Rigal-Huguet, Francoise
    Litzow, Mark
    O'Brien, Susan
    Zugmaier, Gerhard
    Gao, Shan
    Nagorsen, Dirk
    Forman, Stephen J.
    Topp, Max S.
    BLOOD ADVANCES, 2019, 3 (20) : 3033 - 3037
12345